Intra-Cellular (ITCI) | Stock Overview & Key Data
Intra-Cellular Performance Comparison
Stock Range
Today's Range
Low: $131.87
High: $131.87
on June 20, 2025
52 Week Range
Low: $64.09
High: $131.98
on May 20, 2024
on April 1, 2025
All-Time High: $131.98 on March 31, 2025
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$14.0B
EPS
-0.73
P/E Ratio (TTM)
-183.15
Forward P/E
507.19
P/B Ratio
12.20
PEG Ratio
507.19
Div. Yield
N/A
ROE
-8.58%
Beta
0.462
Debt to Equity
1.48
Financial Highlights
Profitability
Gross Margin
89.76%
Operating Margin
-14.66%
Profit Margin
-10.97%
Returns and Earnings
Return on Assets (TTM)
-6.96%
Return on Equity (TTM)
-8.58%
EBITDA
$-116.2M
Net Income (TTM)
$-74.7M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$6.41
Quarterly Revenue Growth (YoY)
50.80%
Quarterly Earnings Growth (YoY)
51.49%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Intra-Cellular ITCI | 14.05B Large-cap | 0.14% | 0.45% | 56.54% | 82.52% | 56.54% | 92.68% | 104.13% | 700.67% |
| Zoetis ZTS | 63.73B | -1.63% | -7.29% | -7.89% | -11.87% | -11.75% | -26.34% | -3.23% | -12.26% |
| Haleon Plc - ADR HLN | 41.72B Large-cap | 1.83% | -9.02% | -13.45% | -12.60% | -5.93% | -14.37% | 45.81% | 19.84% |
| United Therapeutics UTHR | 19.33B Large-cap | 4.24% | 9.54% | 50.21% | 42.01% | 23.10% | 24.59% | 114.46% | 326.34% |
| Neurocrine NBIX | 13.75B Large-cap | -2.95% | -3.65% | 5.67% | 26.25% | -0.81% | 19.95% | 26.32% | 30.95% |
| Viatris VTRS | 11.77B Large-cap | 6.53% | -4.26% | 8.24% | 16.74% | -18.60% | -12.77% | 15.68% | -35.36% |
Ownership & Short Interest
Insider Ownership
2.48%
Institutional Ownership
96.45%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
3M
Average 90-Day Volume
2M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ITCI's 52-week high and low?
- In the last 52 weeks, Intra-Cellular reached a high of $131.98 (on April 1, 2025) and a low of $64.09 (on May 20, 2024).
- What is the market cap and P/E ratio for ITCI?
- Curious about Intra-Cellular's size and valuation? Its market capitalization stands at 14.05B. When it comes to valuation, the P/E ratio (trailing twelve months) is -183.15, and the forward P/E (looking ahead) is 507.19.
- Does ITCI pay dividends? If so, what's the yield?
- As for dividends, Intra-Cellular isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Intra-Cellular's main competitors or similar companies to consider before investing?
When looking at Intra-Cellular, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Zoetis
ZTS63.73B Healthcare Drug Manufacturers - Specialty & Generic -26.34% -3.23% Haleon Plc - ADR
HLN41.72B Healthcare Drug Manufacturers - Specialty & Generic -14.37% 45.81% United Therapeutics
UTHR19.33B Healthcare Drug Manufacturers - Specialty & Generic 24.59% 114.46% Neurocrine
NBIX13.75B Healthcare Drug Manufacturers - Specialty & Generic 19.95% 26.32% Viatris
VTRS11.77B Healthcare Drug Manufacturers - Specialty & Generic -12.77% 15.68% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Intra-Cellular Therapies Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Intra-Cellular's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -8.58%, the Debt to Equity ratio from the most recent quarter is 1.48, and its Gross Profit Margin stands at 89.76%.
- What is the recent revenue and earnings growth for ITCI?
- Looking at Intra-Cellular's growth, its revenue over the trailing twelve months (TTM) was $681M. Compared to the same quarter last year (YoY), quarterly revenue grew by 50.80%, and quarterly earnings saw a YoY growth of 51.49%.
- How much of ITCI stock is held by insiders and institutions?
- Wondering who owns Intra-Cellular stock? Company insiders (like executives and directors) hold about 2.48% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 96.45%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.